Q-omics provides the consensus-scored SNX18P14 profile across patient tissues and cancer cell-line models. SNX18P14 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNX18P14 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, SNX18P14 RNA expression shows 8,126 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, THCA, and THYM as cancer lineages where SNX18P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX18P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX18P14 survival associations across molecular data types. SNX18P14 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX18P14 RNA expression–survival associations across cancer types. High SNX18P14 expression shows unfavorable associations in COAD, UCEC, MESO and STAD, but favorable associations in BRCA and LAML. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SNX18P14 RNA expression.
This table summarizes SNX18P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNX18P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX18P14 shows lower tumor expression in THCA and higher tumor expression in KIRP, KIRC and LIHC. The THCA box plot shows higher SNX18P14 RNA expression in normal versus tumor tissue (log2 FC = −0.826, t-test p < 0.001).
This table shows molecular features associated with SNX18P14 in patient tissues and cancer cell lines. In patient samples, SNX18P14 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
